FDA Accepts SNDAs For Pfizer's Braftovi + Mektovi

Pfizer Inc. (PFE) Tuesday said the Food and Drug Administration accepted Supplemental New Drug Applications (sNDAs) for BRAFTOVI plus MEKTOVI for patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.